Friday - December 27, 2024

Determining Likely Response to Anti-Inflammatory and Pro-Resolving Therapies for Cardiovascular Disease Non-Invasively

2024-10-22

ALEXANDRIA, Virginia, Oct. 22 -- ELUCID BIOIMAGING INC., Boston, Massachusetts has been assigned a patent (No. US 12125572 B2, initially filed Aug. 9, 2023) developed by four inventors Andrew J. Buckler, Boston, Massachusetts; Ulf Hedin, Ronninge, Sweden; Ljubica Matic, Solna, Sweden; and Matthew Phillips, Boston, Massachusetts, for "Determining likely response to anti-inflammatory and pro-resolving therapies for cardiovascular disease non-invasively." . . .

Information Request Form

Name:
Category that best fits the type of business or agency you are affiliated with:	Government Newspaper / Media Business Public Policy Individual / Student Educators
Company Name:
Email:
Phone:
State:

I'd like to have a copy of this article mailed to me.

To also receive a free sample of other Targeted News products check the appropriate boxes below.
Golf Handicap site (FairwayFiles.com)
Products marked with ** can be customized by keywords or areas of interest. If you select them please specify your keywords in the box below:

If we need to contact you please specify your preferred contact method. Have a representative contact me by phone
Have a representative contact me via email

Additonal questions or comments:

Click here for more information or a free trial

Existing Customer Login

Determining Likely Response to Anti-Inflammatory and Pro-Resolving Therapies for Cardiovascular Disease Non-Invasively

Information Request Form

Copyright Targeted News Service 2024